Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016
BEIJING, March 20, 2026 /PRNewswire/ — A news report from chinadaily.com.cn: https://static.prnasia.com/pro/fec/jwplayer-7.12.1/jwplayer.js jwplayer.key=”3Fznr2BGJZtpwZmA+81lm048ks6+0NjLXyDdsO2YkfE=”…